Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Hypoxia inducible factor 2-alpha (HIF2α) mediates cellular responses to hypoxia and is over-expressed in glioblastoma (GBM). PT2385 is an oral HIF2α inhibitor with in vivo activity against GBM. A two-stage single-arm open-label phase II study of adults with GBM at first recurrence following chemoradiation with measurable disease was conducted through the Adult Brain Tumor Consortium. PT2385 was administered at the phase II dose (800 mg b.i.d.). The primary outcome was objective radiographic response (ORR = complete response + partial response, CR + PR); secondary outcomes were safety, overall survival (OS), and progression free survival (PFS). Exploratory objectives included pharmacokinetics (day 15 Cmin), pharmacodynamics (erythropoietin, vascular endothelial growth factor), and pH-weighted amine- chemical exchange saturation transfer (CEST) MRI to quantify tumor acidity at baseline and explore associations with drug response. Stage 1 enrolled 24 patients with early stoppage for ≤ 1 ORR. Of the 24 enrolled patients, median age was 62.1 (38.7–76.7) years, median KPS 80, MGMT promoter was methylated in 46% of tumors. PT2385 was well tolerated. Grade ≥ 3 drug-related adverse events were hypoxia (n = 2), hyponatremia (2), lymphopenia (1), anemia (1), and hyperglycemia (1). No objective radiographic responses were observed; median PFS was 1.8 months (95% CI 1.6–2.5) and OS was 7.7 months (95% CI 4.9–12.6). Drug exposure varied widely and did not differ by corticosteroid use (p = 0.12), antiepileptics (p = 0.09), or sex (p = 0.37). Patients with high systemic exposure had significantly longer PFS (6.7 vs 1.8 months, p = 0.009). Baseline acidity by pH-weighted CEST MRI correlated significantly with treatment duration (R2 = 0.49, p = 0.017). Non-enhancing infiltrative disease with high acidity gave rise to recurrence. PT2385 monotherapy had limited activity in first recurrent GBM. Drug exposure was variable. Signals of activity were observed in GBM patients with high systemic exposure and acidic lesions on CEST imaging. A second-generation HIF2α inhibitor is being studied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Self-citationHIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871 · cited 1×
“HIFs have been shown to be critical for mediating cell metabolism under hypoxia, shifting glucose metabolism from oxidative phosphorylation to glycolysis [20, 21], resulting in accumulation of lactic acid and acidification of the tumor microenvironment [22].”
BackgroundHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354 · cited 1×
“In gliomas, HIF2α is expressed in glioma cells but not in normal neural progenitors or glia [34, 35] and may be clinically relevant as HIF2α expression in the REMBRANDT glioma database (n = 834) showed higher HIF2α expression in tumors that was correlated with worsened patient survival [34].”
BackgroundStupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
Self-citationWen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168 · cited 2×
“Standard of care treatment includes maximal safe surgery followed by chemoradiotherapy with temozolomide [5].”
BackgroundSelf-citationHeddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714 · cited 2×
“Ongoing drug development has resulted in a second-generation compound (i.e., belzutifan) that was recently FDA-approved for the treatment of tumors in patients with von-Hippel Lindau syndrome [30].”
BackgroundCourtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393 · cited 5×
“These time points were selected based on experience from prior studies of this agent [33] indicated that pretreatment and 6 h-post-dose time points provide optimal assessment of trough, maximum observed plasma concentrations, and steady state (i.e., Day 15 C min ).”
BackgroundMethodInfluentialA Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336
Research works printed but not linked: 34
- Stupp R, Mason W, van den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 352(10):987–996 · DOI · Paper page
- Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma : the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926. https://doi.org/10.1016/S1470-2045(12)70265-6 · DOI · Paper page
- Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954–1963. https://doi.org/10.1056/NEJMOA1707358/SUPPL_FILE/NEJMOA1707358_DISCLOSURES.PDF · doi:10.1056/nejmoa1707358/suppl_file/nejmoa1707358_disclosures.pdf
- Weller M, Butowski N, Tran DD et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-X · DOI · Paper page
- Reardon DA, Kim TM, Frenel JS et al (2021) Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 127(10):1620–1629. https://doi.org/10.1002/CNCR.33378 · DOI
- Reardon DA, Brandes AA, Omuro A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 6(7):1003–1010. https://doi.org/10.1001/JAMAONCOL.2020.1024 · DOI · Paper page
- Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S (2005) Hypoxia-induced dedifferentiation of tumor cells—a mechanism behind heterogeneity and aggressiveness of solid tumors. Semi Cell Dev Biol 16:554–563 · DOI · Paper page
- Harris AL (2002) Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47. https://doi.org/10.1038/nrc704 · DOI · Paper page
- Yu T, Tang B, Sun X (2017) Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med J 58(3):489. https://doi.org/10.3349/ymj.2017.58.3.489 · DOI · Paper page
- Semenza GL, Agani F, Booth G et al (1997) Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51(2):553–555 · DOI · Paper page
- Takeda N, O’Dea EL, Doedens A et al (2010) Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev 24(5):491–501. https://doi.org/10.1101/gad.1881410 · DOI · Paper page
- Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7(3):205–213
- Dengler VL, Galbraith MD, Espinosa JM (2014) Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol 49(1):1–15. https://doi.org/10.3109/10409238.2013.838205 · DOI · Paper page
- Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS (2017) Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer 3(7):529–541. https://doi.org/10.1016/j.trecan.2017.05.002 · DOI
- Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891–899. https://doi.org/10.1038/NRC1478 · DOI · Paper page
- Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622. https://doi.org/10.1038/NRN2175 · DOI · Paper page
- Gatenby RA, Frieden BR (2004) Information dynamics in carcinogenesis and tumor growth. Mutat Res-Fundam Mol Mech Mutagen 568(2):259–273. https://doi.org/10.1016/j.mrfmmm.2004.04.018 · DOI
- Corbet C, Feron O (2017) Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer 17(10):577–593. https://doi.org/10.1038/NRC.2017.77 · DOI · Paper page
- Griffiths L, Stratford IJ (1998) The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation. Int J Radiat Oncol Biol Phys 42(4):877–883. https://doi.org/10.1016/S0360-3016(98)00360-5 · doi:10.1016/s0360-3016(98)00360-5
- Shi Q, Le X, Wang B et al (2001) Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 20(28):3751–3756. https://doi.org/10.1038/SJ.ONC.1204500 · DOI · Paper page
- Hjelmeland AB, Wu Q, Heddleston JM et al (2011) Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 18(5):829–840. https://doi.org/10.1038/CDD.2010.150 · DOI · Paper page
- Wang YL, Yao J, Chakhoyan A et al (2019) Association between tumor acidity and hypervascularity in human gliomas using pH-weighted amine chemical exchange saturation transfer echo-planar imaging and dynamic susceptibility contrast perfusion MRI at 3T. AJNR Am J Neuroradiol 40(6):979–986. https://doi.org/10.3174/AJNR.A6063 · DOI
- Yao J, Chakhoyan A, Nathanson DA et al (2019) Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro-oncology 21(9):1184–1196. https://doi.org/10.1093/NEUONC/NOZ078 · DOI
- Renfrow JJ, Soike MH, West JL et al (2020) Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. https://doi.org/10.1038/S41598-020-72290-2 · DOI · Paper page
- Wehn PM, Rizzi JP, Dixon DD et al (2018) Design and activity of specific Hypoxia-Inducible Factor-2α (HIF-2α) inhibitors for the treatment of clear cell renal cell carcinoma: discovery of clinical candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem 61(21):9691–9721. https://doi.org/10.1021/acs.jmedchem.8b01196 · DOI · Paper page
- Courtney K, Infante J, Lam E, et al (2016) A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. In: ASCO Meeting Abstracts · DOI · Paper page
- Nusblat LM, Tanna S, Roth CM (2020) Gene silencing of HIF-2α disrupts glioblastoma stem cell phenotype. Cancer Drug Resist 3(2):199. https://doi.org/10.20517/CDR.2019.96 · DOI
- Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14(2):307–320. https://doi.org/10.1007/s13311-016-0507-6 · DOI · Paper page
- Ellingson BM, Bendszus M, Boxerman J et al (2015) Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-oncology 17(9):1188–1198. https://doi.org/10.1093/NEUONC/NOV095 · DOI · Paper page
- Harris RJ, Cloughesy TF, Liau LM et al (2015) pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-oncology 17(11):1514–1524. https://doi.org/10.1093/NEUONC/NOV106 · doi:10.1093/neuonc/nov106
- Harris RJ, Yao J, Chakhoyan A et al (2018) Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magn Reson Med 80(5):1962–1978. https://doi.org/10.1002/MRM.27204 · DOI
- Yao J, Ruan D, Raymond C et al (2018) Improving B 0 correction for pH-weighted amine proton Chemical Exchange Saturation Transfer (CEST) imaging by use of k-means clustering and lorentzian estimation. Tomography 4(3):123–137. https://doi.org/10.18383/J.TOM.2018.00017 · doi:10.18383/j.tom.2018.00017
- Xie C, Gao X, Sun D et al (2018) Metabolic profiling of the novel hypoxia-inducible factor 2α inhibitor PT2385 in vivo and in vitro. Drug Metab Dispos 46(4):336–345. https://doi.org/10.1124/dmd.117.079723 · DOI
- Hirota T, Eguchi S, Ieiri I (2013) Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 28(1):28–37. https://doi.org/10.2133/dmpk.dmpk-12-rv-085 · DOI
Cited by
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control
Cheng, X., Prange-Barczynska, M., Fielding, J. W., Zhang, M., Burrell, A. L., Lima, J. D. C. C., Eckardt, L., Argles, I. L. A., Pugh, C. W., Buckler, K. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133194 · Cited by 62
Perspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11
Metadata
- Authors
- Strowd, R., Ellingson, B., Raymond, C., Yao, J., Wen, P. Y., Ahluwalia, M., Piotrowski, A., Desai, A., Clarke, J. L., Lieberman, F. S., Desideri, S., Nabors, L. B., Ye, X., & Grossman, S.
- Venue
- Journal of Neuro-Oncology
- Published
- 2023-10
- Volume
- 165
- Issue
- 1
- Pages
- 101-112
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W4387845005
- Cited by
- 36
- References
- 15
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Funders
- National Institutes of Health (UM1CA137443)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. https://app.cochat.ai/papers/10.1007/s11060-023-04456-7
- The paper
- Strowd, R., Ellingson, B., Raymond, C., Yao, J., Wen, P. Y., Ahluwalia, M., Piotrowski, A., Desai, A., Clarke, J. L., Lieberman, F. S., Desideri, S., Nabors, L. B., Ye, X., & Grossman, S. (2023). Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-023-04456-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.